The development achievements of the domestic pharmaceutical bio industry's immuno-oncology drugs will be presented at an overseas conference. Hanmi Pharmaceutical, GC Cell, Abion Bio, ST Cube, and Y-Biologics, among others, have completed preparations to emerge into the international stage by disclosing positive clinical trial results. 

In particular, some companies are conducting clinical trials for combination therapies that utilize their approved immuno-oncology and targeted therapy drugs. They are aiming to increase the chances of commercialization by combining the drugs with verified therapies.

Bispecific antibodies emerge as a global R&D trend, Korean companies also

Son, Hyung Min(shm@dailypharm.com)